Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Review, H2 2016

  • ID: 3832305
  • Report
  • 42 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Bionomics Limited
  • Novartis AG
  • OncoTherapy Science, Inc.
  • Selvita S.A.
  • MORE
Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

‘Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Review, H2 2016’, provides in depth analysis on Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1)
- The report reviews Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Bionomics Limited
  • Novartis AG
  • OncoTherapy Science, Inc.
  • Selvita S.A.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Overview

Therapeutics Development

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Stage of Development

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Therapy Area

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Indication

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Companies

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Products under Development by Universities/Institutes

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Arrien Pharmaceuticals, LLC

Bionomics Limited

Novartis AG

OncoTherapy Science, Inc.

Selvita S.A.

SignalChem Lifesciences Corp

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Drug Profiles

ARN-7016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit MELK for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTS-167 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEL-128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MELK for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MELK for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target FOXM1, MELK, HJURP, VEGFR-1 and VEGFR-2 for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Dormant Projects

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) - Featured News & Press Releases

Mar 17, 2016: The Phase I clinical study of OTS167, MELK specific inhibitor, in Australia Completed

Feb 29, 2016: Publication of a paper describing the possible effect of a MELK inhibitor OTS167 on kidney cancer

Feb 26, 2016: Publication for possible biomarkers of OTS167, MELK inhibitor

Feb 12, 2016: Publication of a paper describing the possible effect of a MELK inhibitor, OTS167, on small cell lung cancer

Jan 25, 2016: The commencement of Phase I/II clinical study of OTS167, MELK specific inhibitor, for Acute Myeloid Leukemia patients in USA

Jan 05, 2016: MELK inhibitor, OTS167, Phase I clinical study commencement in Australia

Jun 18, 2015: The commencement of patient enrollment in Phase I clinical study of OTS167, a novel small molecule compound targeting cancer stem cells

Apr 15, 2013: Selvita Reports Data from SEL128 Oncology Program At AACR Annual Meeting 2013

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 42List of Tables

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Arrien Pharmaceuticals, LLC, H2 2016

Pipeline by Bionomics Limited, H2 2016

Pipeline by Novartis AG, H2 2016

Pipeline by OncoTherapy Science, Inc., H2 2016

Pipeline by Selvita S.A., H2 2016

Pipeline by SignalChem Lifesciences Corp, H2 2016

Dormant Projects, H2 2016 36List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Top 10 Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Bionomics Limited
  • Novartis AG
  • OncoTherapy Science, Inc.
  • Selvita S.A.
  • MORE
Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) Maternal embryonic leucine zipper kinase is an enzyme encoded by the MELK gene. It is involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation. It acts as a regulator of cell cycle, notably by mediating phosphorylation of CDC25B, promoting localization of CDC25B to the centrosome and the spindle poles during mitosis. It plays a key role in cell proliferation and carcinogenesis.

Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Our latest report Maternal Embryonic Leucine Zipper Kinase – Pipeline Review, H2 2016, outlays comprehensive information on the Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Maternal Embryonic Leucine Zipper Kinase (Protein Kinase Eg3 or Tyrosine Protein Kinase MELK or Protein Kinase PK38 or MELK or EC 2.7.11.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Arrien Pharmaceuticals, LLC
Bionomics Limited
Novartis AG
OncoTherapy Science, Inc.
Selvita S.A.
SignalChem Lifesciences Corp
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll